CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2022 American Transplant Congress (ATC) with over 50 oral and scientific poster presentations. CareDx will also be sponsoring a symposium, three product theatres, and an Innovation Day session

CareDx Innovation Showcased in Record-Breaking Number of Scientific Abstracts with Over 50 Presented at 2022 Transplant Congress

SAN DIEGO--(BUSINESS WIRE)---- $CDNA #CareDxInc--CareDx, Inc. (CDNA) is Being Investigated by Multiple Government Agencies for Improper and Illegal Schemes Designed to Inflate Revenue

Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against CareDx, Inc. (CDNA)

New York, New York--(Newsfile Corp. - May 31, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the "Class Period"), of the important July 22, 2022 lead plaintiff deadline.SO WHAT: If you purchased CareDx securities during the Class Period you may be entitled to compensation without payment of any out of...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CareDx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CDNA

SAN FRANCISCO--(BUSINESS WIRE)---- $CDNA #CDNA--CDNA INVESTORS: July 22, 2022 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

CDNA INVESTORS: July 22, 2022 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

New York, New York--(Newsfile Corp. - May 28, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2022.SO WHAT: If...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages CareDx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CDNA

San Diego, California--(Newsfile Corp. - May 26, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of CareDx, Inc. (NASDAQ: CDNA) common stock between February 24, 2021 and May 5, 2022, inclusive (the "Class Period") have until July 22, 2022 to seek appointment as lead plaintiff in Plumbers & Pipefitters Local Union #295 Pension Fund v. CareDx, Inc., No. 22-cv-03023 (N.D. Cal.). The CareDx class action lawsuit charges...

INVESTOR DEADLINE: CareDx, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CDNA

New York, New York--(Newsfile Corp. - May 26, 2022) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA).CLICK HERE FOR MORE DETAILS: https://claimyourloss.com/securities/caredx-inc-loss-submission-form/?id=27790&from=5This lawsuit is on behalf of all persons or entities who purchas

CDNA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of CAREDX, INC. Shareholders

SAN FRANCISCO , May 26, 2022 /PRNewswire/ -- Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Class Period: Feb. 24, 2021 – May 5, 2022 Lead Plaintiff Deadline: July 22, 2022 Visit: www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: CDNA@hbsslaw.com         844-916-0895 CareDx, Inc. (CDNA) Securities Fraud Class Action: The complaint alleges that throughout the Class Period, CareDx reported growing revenue and strong demand in the Company's testing services segment.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired CareDx securities between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”). Investors have

CAREDX ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against CareDx, Inc. and Encourages Investors to Contact the Firm

Shareholder Alert: Robbins LLP informs Shareholders of Class Action Against CareDx, Inc. (CDNA)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CareDx, Inc. (NASDAQ: CDNA) between February 24, 2021 and May 5, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2022. SO WHAT: If you purchased CareDx securities during the Class Period you may be entitled to compensation without payme

EQUITY ALERT: Rosen Law Firm Encourages CareDx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CDNA

Did you lose money on investments in CareDx?  If so, please visit CareDx, Inc. Shareholder Class Action Lawsuit or contact  Joe Seidman at (212) 951-2025 or seidman@bernlieb.com to discuss your rights.

CareDx, Inc. (NASDAQ: CDNA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against CareDx Inc. (NASDAQ: CDNA)

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2022 to file lead plaintiff applications in a securities class action lawsuit against CareDx, Inc. (“CareDx” or the “Company”) (NasdaqGM: CDNA), if they purchased the Company's shares between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”). This action is pending in the United States Distric

CAREDX SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CareDx, Inc. - CDNA

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) common stock between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”). CareDx investors have until July 22, 2022 to file a lead plaintiff motion. If you suffered a loss on your CareDx investments

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of CareDx, Inc. (CDNA) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) common stock between February 24, 2021 and May 5, 2022, inclusive (the “Class Period”). CareDx investors have until July 22, 2022 to file a lead plaintiff motion. Investors suffering losses on their CareDx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of CareDx, Inc. (CDNA) Investors

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) and certain of its executive officers (collectively, “Defendants”). The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securiti

SHAREHOLDER ALERT - Labaton Sucharow Notifies CareDx, Inc. Investors of the Filing of a Class Action Lawsuit

CareDx Expands Transplant Portfolio in Europe CareDx Expands Transplant Portfolio in Europe

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 22, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

CareDx Investor Alert

Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction

Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring

CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference

CareDx, Inc (NASDAQ:CDNA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Inc. Operator Good day, and welcome to the CareDx First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

CareDx, Inc (CDNA) CEO Reg Seeto on Q1 2022 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates

OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection

CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection

Transplants are in high demand; this company is making the process of getting one smoother.

These Charts Explain Why I'm Holding This Healthcare Company

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Board member Hannah Valantine MD, a recognized leader in driving heart transplantation innovations and health equity, has received the 2022 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation (ISHLT).

News for CareDx Stock (CDNA)